Health Care Service Corporation Names Carolyn H. Clift as Senior Vice President and First Chief Diversi...(ahoma and Texas. A Mutual Legal Reserve ...),Health
Navigation Links
Health Care Service Corporation Names Carolyn H. Clift as Senior Vice President and First Chief Diversity Officer
Date:6/17/2009
ahoma and Texas. A Mutual Legal Reserve Company, HCSC is an independent licensee of the Blue Cross and Blue Shield Association. HCSC has a rating of AA- (Very Strong) from Standard and Poor's, Aa3 (Excellent) from Moody's and A+ (Superior) from A.M. Best Company. For more information, visit www.HCSC.com.
'/>"/>
| SOURCE Health Care Service Corporation Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
(Date:11/21/2009)...e medical apparel company launches men,s lab coats... San Clemente, Calif. (PRWEB) November 21, 2009...pparel, today announced the launch of its men,s la...ading international trade fair for the medical ind...rates its men,s collection with three varying lab ...
(Date:11/21/2009)... Dental Group merges their practice with that of E... (PRWEB) November 21, 2009 -- The... David Gibson, Dr. Dean Cloutier, Dr. John Plachty...growing practice with that of esteemed colleague D... he wanted to retire from dentistry in order to co...
(Date:11/20/2009).../PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals C...reholders will be held on Monday, December 21, 200...val of two special resolutions. The first special ... all or substantially all of the assets of NUCRYST...sset purchase agreement dated November 10, 2009 am...
(Date:11/20/2009)...PRNewswire/ -- Following a recall by Unilever The ...ale Shedd,s Country Crock ® Side Dishes DELUX...® Side Dishes DELUXE Four Cheese Pasta due to...ing code dates and UPCs are affected: ,, Shedd... Broccoli Rice 21 oz, UPC 027400218316, Best By NO...
(Date:11/20/2009)...wire-USNewswire/ -- The American Dental Associatio...tration (FDA) to establish appropriate classificat...concern about the safety of whitening products tha...ofessional consultation or examination by a dentis...emically based tooth whitening or bleaching agents...
Breaking Medicine News(10 mins):Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:New Haven Dental Group Expands Their Vision 2Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2[0] Medelita Introduces Men's Lab Coat Collection [0] New Haven Dental Group Expands Their Vision [0] NUCRYST Announces Special Meeting of Shareholders[0] Stop & Shop Alerts Customers to Voluntary Recall by Unilever[0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products
... sustain a traumatic brain injury (TBI) each year,... long-term disability. It also is a major cause of...personnel.
Despite the enormity of the pro...ped for traumatic brain injuries in over 30 years....
..., percutaneous coronary intervention (PCI, angiopl...rm risk of major cardiac events among heart attack...study.
Cardiac ischemia is caused by insuf...e supply of oxygen to the heart muscle), but can b...
...aunched a comprehensive immunization programme acr... aimed at covering as many as 48 milllion people. ... the yellow fever, resurging in the region and is ... is a public-private partnership focused on increa...
... disability compensation for veterans, the U.S. De... how it evaluates former military personnel for se...SD) and determines the payment amounts they merit,...led inconsistencies in compensation levels awarded...
...ational Toxicology Program (NTP), has produced str...lent chromium (chromium 6) causes cancer when it ... chromium compounds are often used in electroplati...d developed malignant tumors upon administration o...
...relation between an extreme form of sleep disorder...of dementia or parkinsonism.
Patients wit...Lewy body dementia, Parkinsons disease or multiple...researchers led by Bradley Boeve at Mayo Clinic. ...
Other Medicine News:Health News:Death and Disability from Brain Injury Reduced, Emory Researchers Report 2Health News:Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With 'silent' Ischemia 2Health News:WHO Launches Yellow Fever Initiative for West Africa 2Health News:VA Should Revise Its Methods for Evaluating PTSD in Ex-military Personnel 2Health News:VA Should Revise Its Methods for Evaluating PTSD in Ex-military Personnel 3Health News:Researchers Find Link Between Sleep Disorder and Dementia 2Death and Disability from Brain Injury Reduced, Emory Researchers ReportAngioplasty Reduces Long-term Cardiac Risk in Heart Patients With 'silent' IschemiaWHO Launches Yellow Fever Initiative for West AfricaVA Should Revise Its Methods for Evaluating PTSD in Ex-military PersonnelHexavalent Chromium in Drinking Water Causes Cancer in MiceResearchers Find Link Between Sleep Disorder and Dementia
(Date:11/20/2009)... , , NATICK, Mass. and LONDON, Nov. 20 /...tion (NYSE: BSX ) today announced that it has re...g Administration (FDA) and CE Mark approval to mar...ent for the treatment of malignant esophageal stri... with resectable or non-resectable esophageal canc...
(Date:11/20/2009)... , , FRANKLIN LAKES, N.J., Nov. 20 /PRNews...ny) (NYSE: BDX ) today announced the completion ..., Michigan-based company that develops and manufac...latforms. ,, In May 2009, BD and HandyLab annou...commercialize molecular assays on the HandyLab Jag...
(Date:11/19/2009)... , , BIRMINGHAM, Ala., Nov. 19 /PRNewswi...asdaq: BCRX ) today announced the pricing of a pu...ock at $9.75 per share, resulting in gross proceed...offered by BioCryst pursuant to an effective shelf...Securities and Exchange Commission. BioCryst has ...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Central Florida is International Destination for Unique State of the Art Procedure to Treat Common Digestive Ailment 50762 1Central Florida is International Destination for Unique State of the Art Procedure to Treat Common Digestive Ailment 50762 2Central Florida is International Destination for Unique State of the Art Procedure to Treat Common Digestive Ailment 50762 3The GenoMEL project identifies a new region of the genome associated with the risk of melanoma 50759 1The GenoMEL project identifies a new region of the genome associated with the risk of melanoma 50759 2New national genome center launched 9110 1New national genome center launched 9110 2New national genome center launched 9110 3...Pharmaceuticals, Inc., a privately-held biotechnol...nt of novel therapeutics for cardiovascular and,in...aised $60 million in a,preferred stock financing. ...,s two lead antithrombotic clinical candidates, be...oping as best-in-class compounds to,replace existi...
....,(Nasdaq: ARNA ) today announced positive result... trial of APD791 to evaluate the compound,s safety...Arena,s internally,discovered oral drug candidate ...and other related conditions., The Phase 1b trial...d,multiple-ascending dose trial in 50 healthy adul...
Other Medicine Technology:Portola Completes $60 Million Financing to Advance Its Therapeutic Programs 2Portola Completes $60 Million Financing to Advance Its Therapeutic Programs 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |